At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 30 target
Drug / intervention
Icotinib +1 moredrug
Likely dose
Icotinib 375 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Determine the Efficacy and Safety of High Dose Icotinib Combined With Stereotatic Radiosurgery for NSCLC Patients Harboring EGFR Mutation With Brain Metastases
In Brief
A Phase 2 clinical trial evaluating Icotinib and SRS for Non-small Cell Lung Cancer and Brain Metastases. Targeting 30 participants across 1 site.
Detailed Summary
This trail is designed to assess the efficacy and safety of high dose Iconitib combined with SRS for NSCLC patients harboring EGFR mutation with brain metastases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Brain Metastases
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedApr 2016
Primary CompletionDec 2021
Study CompletionDec 2022
TodayJul 2026
First PostedApr 1, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2021
Study CompletionDec 1, 2022
TodayJul 1, 2026
Enrollment to primary: 5.8 yearsPosted 10.3 years ago
Interventions
Icotinibdrug
375 mg Tid (1125 mg per day) until intracranial PD.
SRSradiation
If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.